Search

everythinglearnresearchcommunity

for

Search:↓

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Ruxolitinib cream may help treat severe hair loss in children.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Topical tofacitinib is effective and safe for treating alopecia areata.

A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

JAK inhibitors can enter the skin through hair follicles using a unique pathway.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Baricitinib works better than methotrexate for severe alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.

Upadacitinib may effectively treat resistant lichen planopilaris.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.